756 related articles for article (PubMed ID: 19476437)
1. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
[TBL] [Abstract][Full Text] [Related]
2. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
4. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
5. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
6. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
7. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
8. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.
Vaccher E; Spina M; Talamini R; Zanetti M; di Gennaro G; Nasti G; Tavio M; Bernardi D; Simonelli C; Tirelli U
Clin Infect Dis; 2003 Dec; 37(11):1556-64. PubMed ID: 14614680
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
[TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
11. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
14. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998.
Glaser SL; Clarke CA; Gulley ML; Craig FE; DiGiuseppe JA; Dorfman RF; Mann RB; Ambinder RF
Cancer; 2003 Jul; 98(2):300-9. PubMed ID: 12872349
[TBL] [Abstract][Full Text] [Related]
15. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
17. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
18. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
Amara S; Dezube BJ; Cooley TP; Pantanowitz L; Aboulafia DM
Clin Infect Dis; 2006 Nov; 43(9):1198-205. PubMed ID: 17029142
[TBL] [Abstract][Full Text] [Related]
19. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
Simonelli C; Tedeschi R; Gloghini A; Bortolin MT; Spina M; Bidoli E; Cinelli R; De Paoli P; Carbone A; Tirelli U
Clin Infect Dis; 2005 Apr; 40(7):1022-7. PubMed ID: 15824995
[TBL] [Abstract][Full Text] [Related]
20. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]